Tdap Vaccine in Post-Partum Women

Summary

Monitoring immune response and longevity in serum and milk after Tdap administration to postpartum women. The clinical trial will involve women (aged 18 - 45 years) who have just delivered full-term infants (greater than or equal to 37 completed weeks of gestation) at Vanderbilt University Medical Center. The enrollment period will be fifteen months. The duration is over two years of observation.

Timeline

Start

2012-10-26

Primary completion

2015-08-28

Completion

2015-08-28

Drugs

Indications